Open menu
View all staff

Doctor Fay Chinnery

Research Fellow (Health Tech Assmt&Mod)

Connect with Fay

Email: f.chinnery@soton.ac.uk

Address: University Of Southampton Science Park, Enterprise Road, Chilworth, SO16 7NS (View in Google Maps)

ORCID
Publications Biography

Publications

21 publications
Page 1 of 3
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
Andrew Davies,
Sharon Barrans,
Cathy Burton,
Katy Mercer,
Joshua Caddy,
Fay Chinnery,
Laura Day,
Diana Fernando,
Kirit Ardeshna,
Graham Collins,
John Radford,
Simon Rule,
Andrew Mcmillan,
Peter Johnson,
& Gareth Griffiths
, 2022 , F1000Research , 9
DOI: 10.12688/f1000research.22318.1
Type: article
How to edit profile
Back to top